PDCD1 and cancer: Disruption of PD-1/PD-L1 interactions through several approaches, such as blockade with monoclonal antibodies targeting either PD-1 or PD-L1, led to an enhancement of anti-cancer immune responses in several tumor models [36,37,38,39,40].